# Bristol-Myers Squibb Company (BMY) — Q4-2023 Earnings Results

**Report date:** 2024-02-02 (before market open)  
**Sector:** Health Care / Pharmaceuticals  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/BMY/earnings/Q4-2023

## Post-Earnings Brief

### Headline

Bristol Myers Squibb Beats on EPS, Stock Up 0.08%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.70 | N/A | +11.62% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management expressed confidence in the company's strategic direction while acknowledging market challenges. They reiterated their commitment to innovation and efficiency.

**Key quotes:**

> Management highlighted strong performance in key therapeutic areas.

> They noted ongoing investments in R&D to drive future growth.

> There was an emphasis on maintaining operational efficiency.

### Guidance Changes

No guidance updates were provided during the earnings call.

### What It Means

Bristol Myers Squibb's earnings report shows a positive surprise in EPS, which may reflect effective cost management and strong product performance. The stock's slight increase of 0.08% suggests that investors are reassured by the company's current performance, despite the lack of revenue data and guidance. The focus on R&D and operational efficiency indicates a long-term growth strategy.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/BMY/earnings/Q4-2023_